5-hydroxytryptophan has been researched along with Cerebellar Ataxia in 11 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Cerebellar Ataxia: Incoordination of voluntary movements that occur as a manifestation of CEREBELLAR DISEASES. Characteristic features include a tendency for limb movements to overshoot or undershoot a target (dysmetria), a tremor that occurs during attempted movements (intention TREMOR), impaired force and rhythm of diadochokinesis (rapidly alternating movements), and GAIT ATAXIA. (From Adams et al., Principles of Neurology, 6th ed, p90)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 7.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 5.27 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "18 patients with degenerative cerebellar ataxia were given for 12 months, high doses of D-L-5 Hydroxytryptophan (16 mg/kg/day) with a peripheral inhibitor of 5-HTP Decarboxylase." | 5.26 | [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan]. ( Adeleine, P; Garde, A; Robert, JM; Trouillas, P, 1981) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 3.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 1.27 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "18 patients with degenerative cerebellar ataxia were given for 12 months, high doses of D-L-5 Hydroxytryptophan (16 mg/kg/day) with a peripheral inhibitor of 5-HTP Decarboxylase." | 1.26 | [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan]. ( Adeleine, P; Garde, A; Robert, JM; Trouillas, P, 1981) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values related to the major symptoms, is proposed." | 1.26 | [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods]. ( Adeleine, P; Bard, J; Brudon, F; Garde, A; Renaud, B; Robert, JM; Trouillas, P, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trouillas, P | 4 |
| Garde, A | 2 |
| Robert, JM | 3 |
| Adeleine, P | 2 |
| Renaud, B | 1 |
| Bard, J | 1 |
| Brudon, F | 1 |
| Wessel, K | 1 |
| Hermsdörfer, J | 1 |
| Deger, K | 1 |
| Herzog, T | 1 |
| Huss, GP | 1 |
| Kömpf, D | 1 |
| Mai, N | 1 |
| Schimrigk, K | 1 |
| Wittkämper, A | 1 |
| Ziegler, W | 1 |
| Manto, M | 1 |
| Hildebrand, J | 1 |
| Godaux, E | 1 |
| Roland, H | 1 |
| Blum, S | 1 |
| Jacquy, J | 1 |
| Chazot, G | 1 |
| Guard, O | 1 |
| Setiey, A | 1 |
| Schott, B | 1 |
| Gracia Naya, M | 1 |
| Pina Latorre, MA | 1 |
| Klein, P | 2 |
| Lees, A | 1 |
| Stern, G | 1 |
| Rohmer, F | 1 |
| Warter, JM | 1 |
| Coquillat, G | 1 |
| Maitrot, D | 1 |
| Kurtz, D | 1 |
| Micheletti, G | 1 |
| Mack, G | 1 |
| Mandel, P | 1 |
3 trials available for 5-hydroxytryptophan and Cerebellar Ataxia
| Article | Year |
|---|---|
Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases.
Topics: 5-Hydroxytryptophan; Cerebellar Ataxia; Cross-Over Studies; Double-Blind Method; Hand Strength; Huma | 1995 |
Cerebeller ataxia.
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Clinical Trials as Topic; Drug Therapy, Combina | 1990 |
[Pharmacological and biochemical approach to a syndrome of action and intention myoclonus in the course of degenerative disease of the nervous system].
Topics: 5-Hydroxytryptophan; Adult; Benzazepines; Cerebellar Ataxia; Clinical Trials as Topic; Diagnosis, Di | 1973 |
8 other studies available for 5-hydroxytryptophan and Cerebellar Ataxia
| Article | Year |
|---|---|
Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Dopamine; Drug Therapy, Combination; Friedreich | 1984 |
[Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
Topics: 5-Hydroxytryptophan; Adult; Benserazide; Cerebellar Ataxia; Female; Friedreich Ataxia; Humans; Male; | 1981 |
[Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Computers; Drug Therapy, Combination; Humans; H | 1982 |
Analysis of fast single-joint and multijoint movements in cerebellar cortical atrophy: failure of L-hydroxytryptophan to improve cerebellar ataxia.
Topics: 5-Hydroxytryptophan; Atrophy; Cerebellar Ataxia; Cerebellar Cortex; Female; Humans; Joints; Male; Mi | 1997 |
[Ramsay-Hunt syndrome and aniridia in 2 monozygotic twins].
Topics: 5-Hydroxytryptophan; Adolescent; Benzodiazepinones; Blood Group Antigens; Cerebellar Ataxia; Disease | 1975 |
[Therapeutic trial in a family with late cerebellar atrophy].
Topics: 5-Hydroxytryptophan; Adult; Cerebellar Ataxia; Humans; Male; Thyrotropin-Releasing Hormone | 1991 |
Cerebellar ataxia.
Topics: 5-Hydroxytryptophan; Cerebellar Ataxia; Humans | 1989 |
Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders.
Topics: 5-Hydroxytryptophan; Adult; Aged; Benserazide; Cerebellar Ataxia; Drug Therapy, Combination; Female; | 1987 |